Dr. Anand S. Srivastava M.S., Ph.D (Editor-in-Chief)

Dr. Anand S. Srivastava

Chairman & Co-founder

Email: anand@giostar.com


Dr. Anand Srivastava has been associated with leading universities and research institutions of the USA, including the University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA. He has helped develop several research programs and has extensive research experience in the field of stem cell research, documented by several publications in revered scientific journals.

Dr. Srivastava is the Chairman and Cofounder of California-based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, USA. GIOSTAR aims to provide stem cell-based therapy to aid those suffering from degenerative or genetic diseases around the world. The company’s primary focus is to discover and develop cures for human diseases with unique stem cell-based therapies and products.


  • Developed animal material-free and serum-free Human embryonic Stem cell culture conditions for treating human diseases.
  • Showed that ES cell injections into developing fetuses take part in the development of all body parts of a living organism.
  • Demonstrated that ES cells are better accepted by transplanted animals compared to adult stem cells.
  • Generated a high number of pre-erythrocytes using glucocorticoid hormone, potentially treating several blood diseases.
  • Showed that ES cells can recognize and repair damaged portions of the brain.
  • Used ES cells to treat Crohn’s disease, a kind of colon cancer.
  • Programmed mammalian fetuses to face future possible infections, aiding in advanced therapy development for fatal diseases like cancer and AIDS.
  • Developed a technique for targeted delivery of drugs and genes to specific fetal tissues without harming normal tissues of the mother and fetus.
  • Showed that plant product curcumin can treat lung cancer cells, helping develop non-toxic, less expensive cancer drugs.

Positions Held

  • Chairman and Co-founder (2019-till date): Cellebration Life Sciences, CA, USA.
  • Chairman & Co-founder (2008-till date): Global Institute of Stem Cell Therapy and Research, San Diego, CA, USA.
  • Visiting Scientist (2009-2012): Department of Stem Cell Biology, Burnham Research Institute for Medical Science, San Diego, CA, USA.
  • Visiting Associate Researcher (2009-2010): Department of Molecular, Cell and Development Biology, University of California Los Angeles (UCLA), CA, USA.
  • Researcher (2008–2009): Stem Cell Core Facility, The Salk Institute for Biological Studies, La Jolla, CA, USA.
  • Associate Project Scientist (2006-2008): Department of Stem Cells and Neurology, School of Medicine, University of California Irvine (UCI), Irvine, CA, USA.
  • Assistant Project Scientist (2000-2006): Cancer Center, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
  • Visiting Fellow (1997-2000): National Research Institute, Nansei, Mie, Japan.


  • Sofía Lopez, Cristina Santana, Diana Esquivel, Daniel Garza, Rangnath Mishra, Anand Srivastava. "Mesenchymal Stem Cell Therapy in Cervical Spine Compression: A Case Report." Mathews J Case Rep. 9(3):156, 2024.
  • Mahmood A, Somani N, Patel D, Mishra R, Srivastava A. "Stem cell secretome-mediated alleviation of scalp psoriasis: A case report." Arch Stem Cell Ther. 5(1):1-4, 2024.
  • Diana Esquivel, Rangnath Mishra, Anand Srivastava. "Mesenchymal Stem Cell Therapy for Treating the Underlying Causes of Diabetes Mellitus and Its Consequences." Current Stem Cell Research & Therapy, 18:1-7, 2023.
  • Esquivel D, Mishra R, Soni P, Seetharaman R, Mahmood A, Srivastava A. "Stem Cells Therapy as a Possible Therapeutic Option in Treating COVID-19 Patients." Stem Cell Rev Rep. 17(1):144-152, 2021.
  • Prabhat Soni, Anand Srivastava. "Mesenchymal stem cells may be a credible alternative therapy to fight with COVID-19 pandemic." J Stem Cell Res Ther. 6(2): 79‒80, 2020.